Back to Search Start Over

Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion.

Authors :
Eser TM
Baranov O
Huth M
Ahmed MIM
Deák F
Held K
Lin L
Pekayvaz K
Leunig A
Nicolai L
Pollakis G
Buggert M
Price DA
Rubio-Acero R
Reich J
Falk P
Markgraf A
Puchinger K
Castelletti N
Olbrich L
Vanshylla K
Klein F
Wieser A
Hasenauer J
Kroidl I
Hoelscher M
Geldmacher C
Source :
Nature communications [Nat Commun] 2023 May 24; Vol. 14 (1), pp. 2952. Date of Electronic Publication: 2023 May 24.
Publication Year :
2023

Abstract

Despite intensive research since the emergence of SARS-CoV-2, it has remained unclear precisely which components of the early immune response protect against the development of severe COVID-19. Here, we perform a comprehensive immunogenetic and virologic analysis of nasopharyngeal and peripheral blood samples obtained during the acute phase of infection with SARS-CoV-2. We find that soluble and transcriptional markers of systemic inflammation peak during the first week after symptom onset and correlate directly with upper airways viral loads (UA-VLs), whereas the contemporaneous frequencies of circulating viral nucleocapsid (NC)-specific CD4 <superscript>+</superscript> and CD8 <superscript>+</superscript> T cells correlate inversely with various inflammatory markers and UA-VLs. In addition, we show that high frequencies of activated CD4 <superscript>+</superscript> and CD8 <superscript>+</superscript> T cells are present in acutely infected nasopharyngeal tissue, many of which express genes encoding various effector molecules, such as cytotoxic proteins and IFN-γ. The presence of IFNG mRNA-expressing CD4 <superscript>+</superscript> and CD8 <superscript>+</superscript>  T cells in the infected epithelium is further linked with common patterns of gene expression among virus-susceptible target cells and better local control of SARS-CoV-2. Collectively, these results identify an immune correlate of protection against SARS-CoV-2, which could inform the development of more effective vaccines to combat the acute and chronic illnesses attributable to COVID-19.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
2041-1723
Volume :
14
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
37225706
Full Text :
https://doi.org/10.1038/s41467-023-38020-8